PDCD1 and melanoma: Immune checkpoint mAbs such as anti-programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) and CTLA-4 have shown durable responses in the treatment of melanoma, non-small cell lung cancer (NSCLC), and renal cancer carcinoma [39].